We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
U.S. President Bush has asked Congress to approve $5.4 billion for the President's Emergency Plan for AIDS Relief (PEPFAR) for fiscal 2008, the last year of the five-year effort to fight HIV/AIDS around the world, the Department of State announced.
The FDA got off to a slow start with new drug application (NDA) approvals in 2007, approving barely more than half as many as it had by this time last year.
Dutch biotech company Crucell announced it will receive up to $5 million from the Aeras Global TB Vaccine Foundation to develop its AdVac-based tuberculosis (TB) vaccine.
Nautilus Biotech announced it has signed a collaboration and license agreement with HanAll Pharmaceutical, based in South Korea, to develop and commercialize three of Nautilus' products: Belerofon, Vitatropin and Eporal.
A court has adjourned a hearing of Novartis' challenge to the Indian patent system to later this month, but activists are still paying attention to the case because of its potential to affect Africa's generic drug supply, according to a U.N. Integrated Regional Information Networks (IRIN) article.
The U.S. HHS has found Hollis-Eden Pharmaceuticals' acute radiation syndrome drug candidate, Neumune, to be "technically unacceptable," the company said.
The UK's Medicines and Healthcare Products Regulatory Agency (MHRA) has issued a public consultation letter seeking proposals on restricting sales of cold medicines containing pseudoephedrine and ephedrine.
Encysive Pharmaceuticals announced that the Australian Therapeutic Goods Administration (TGA) has approved its Thelin 100-mg tablets as a once-daily treatment for pulmonary arterial hypertension.
Zentiva announced it has signed an agreement to acquire 75 percent of the issued share capital of Eczacibasi Generic Pharmaceuticals, a major domestic pharmaceutical supplier in Turkey, for 460 million euros in cash.
Tercica and Insmed, both based in the U.S., announced they have entered a settlement, license and development agreement with Genentech that resolves all outstanding litigation between the companies, including the patent infringement suits brought by Tercica and Genentech against Insmed in the U.S.